Sodium cromoglycate appears to block a step in the chain of events triggered by this union. This property accounts for the prophylactic rather than symptomatic approach to the management of seasonal rhinitis. Sodium cromoglycate has no antihistaminic, anti-inflammatory, or decongestant activity.
Regular dosage is important.
Treatment must not be abruptly discontinued especially where benefit has been obtained. Experience in patients with nasal polyps is limited and, therefore, these patients should be carefully observed while undergoing treatment. Possible immunologic changes resulting in reactions such as polymyositis, pneumonitis and heart failure, urticaria and anaphylaxis have been reported and are being actively investigated. During clinical use there have been, to date, no reports of adverse effects on the mother or the fetus which could be ascribed to the use of sodium cromoglycate. Nevertheless, as with all medications, caution must be exercised during pregnancy.